THE NEW DRUGS WITH FEWER SIDE EFFECTS WILL PROBABLY DO BETTER: Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds.
InstaPundit is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.